(Harrisburg) -- Pennsylvania might move away from a stunningly
expensive prescription drug treatment for Medicaid patients with
Hepatitis C, but the Commonwealth won't save as much as other states.
Missouri is one of the first states to move away from Sovaldi, which costs $1,000 a pill.
Pennsylvania might do the same, but the state's Medicaid program is
waiting on final offers from two competitors that provide other drugs
recently approved by the FDA for Hepatitis C treatment.
Labels: Exclusivity Deals, medicaid, Pennsylvania, Sovaldi, treatment costs